← All trials
NCT06886360
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2025
- Primary completion
- Sep 30, 2027
- Completion date
- Sep 30, 2027
- First posted
- Mar 20, 2025
- Last posted
- Mar 20, 2025
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dr. Falk Pharma GmbHLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.